Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow at a CAGR of 30.7% from 2025 to 2029
Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Growth Projections For The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size During 2025–2029?
The market for duchenne muscular dystrophy (DMD) therapeutics has shown substantial expansion in recent years. It is projected to grow from $11.95 billion in 2024 to $16.38 billion in 2025, achieving a compound annual growth rate (CAGR) of 37.0%. Historically, this growth has been driven by factors such as the increasing prevalence of duchenne muscular dystrophy, enhanced awareness about duchenne muscular dystrophy treatment, rising healthcare spending, and government initiatives.
The duchenne muscular dystrophy (DMD) therapeutics market is projected to experience substantial growth in the upcoming years, with its size expected to reach ” $47.74 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 30.7%. This expansion during the forecast period is primarily driven by increasing investments in duchenne muscular dystrophy treatments, the wider adoption of combination therapies, the emergence of biomarkers, and a rising number of screening programs for duchenne muscular dystrophy. Significant trends anticipated in this period include pioneering treatments for duchenne muscular dystrophy, the ongoing development of targeted therapies, the introduction of novel medications and therapies, innovative disease-modifying therapies, and active drug development initiatives.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12916&type=smp
Which Factors And Drivers Are Influencing The Duchenne Muscular Dystrophy (DMD) Therapeutics Market In 2025?
The escalating count of clinical trials is anticipated to drive forward the expansion of the Duchenne muscular dystrophy (DMD) therapeutics market. Clinical trials, which are research investigations conducted with human participants, aim to evaluate the safety, efficacy, and potential benefits of novel medical treatments, interventions, or drugs. The observed surge in clinical trials specifically targeting Duchenne muscular dystrophy treatment highlights continuous scientific inquiry, innovative breakthroughs, and a broad spectrum of therapeutic possibilities. These advancements are projected to enhance patient results, attract financial backing, and hasten the progress and Availability of Effective Therapies for Duchenne Muscular Dystrophy (DMD). As an illustration, data from Clinicaltrials.Gov, an entity of The National Institutes Of Health (NIH), a US-based government agency dedicated to medical research, showed that in August 2023, the total number of registered clinical trials globally reached 464,218, an increase from 399,496 in 2021, encompassing all 50 states of the United States and 221 countries. Furthermore, reports indicated that 142,700 studies (representing 31% of the total) were registered within the U.S., while 248,310 studies (accounting for 53% of the total) were documented in locations outside the U.S. Therefore, an increasing volume of clinical trials is set to fuel the growth of the duchenne muscular dystrophy (DMD) therapeutics market.
What Are The Segment Types Shaping The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
The duchenne muscular dystrophy (dmd) therapeutics market covered in this report is segmented –
1) By Type: Small Molecules, Biologics
2) By Distribution Channel: Offline, Online
3) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Small Molecules: Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds
2) By Biologics: Gene Therapies, Cell Therapies, Protein Replacement Therapies
How Are Trends Influencing The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
Leading companies operating within the duchenne muscular dystrophy (DMD) therapeutics market are implementing advanced technologies to boost the effectiveness and accessibility of therapies for DMD patients, thereby maintaining their market standing. For example, in July 2023, Bit Bio Ltd., a synthetic biology company based in the UK, launched innovative disease model products designed to accelerate the development of Duchenne muscular dystrophy (DMD) treatments. These particular disease models, known as ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, are human skeletal muscle cells engineered with genetic deletions in the gene responsible for producing dystrophin protein. Reprogrammed from induced pluripotent stem cells (iPSCs), Bit. Bio’s models offer a dependable and scalable supply of human cells for research, thereby resolving issues related to variability and the procurement of primary cells. The models significantly aid in the development of DMD treatments by yielding critical insights into disease mechanisms and prospective therapies. This breakthrough could expedite the work of researchers striving to discover effective treatments for DMD.
Who Are The Core Companies Influencing The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Landscape?
Major companies operating in the duchenne muscular dystrophy (dmd) therapeutics market are CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings PLC, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.
Download The Full Report For Exclusive Market Findings:
Which Geographies Are Emerging As Strong Markets For The Duchenne Muscular Dystrophy (DMD) Therapeutics Industry?
North America was the largest region in the DMD therapeutics market in 2024. The regions covered in duchenne muscular dystrophy (DMD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=12916&type=smp
Browse Through More Reports Similar to the Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2025, By The Business Research Company
Macular Degeneration Treatment Global Market Report 2025
Age Related Macular Degeneration Global Market Report 2025
Duchenne Muscular Dystrophy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
